Sydney-based Pharmaxis (ASX:PXS) has announced further positive results of data analysis from an early trial studying its PXS-5505 in patients with bone marrow cancer. …
Pharmaxis' PXS-5505 cleared to progress to new bone marrow cancer trial
October 6, 2021 Latest NewsBioPharma
Latest Video
Georgia Forrest
New Stories
-
The Dispatched Podcast 'Week in Review' - 20 February
February 20, 2026 - - Podcast -
PhRMA launches new campaign against the backdrop of a more assertive U.S.
February 19, 2026 - - Latest News -
Why does anyone accept a review outcome that simply affirms a settled order
February 19, 2026 - - Latest News -
Wesfarmers Health emerges as growth engine after delivering strong first half
February 19, 2026 - - Australian Biotech -
Telix files for European approval of brain cancer imaging candidate TLX101-Px
February 18, 2026 - - Australian Biotech -
IDT signals turnaround as revenue rises and losses narrow under strategic reset
February 18, 2026 - - Latest News -
Nyrada advances lead candidate into mid-stage trial as momentum builds across programs
February 18, 2026 - - Australian Biotech